The pandemic has transformed the way we manage our lives. Over the past 18 months, we’ve learned to do things differently and not do some things at all, like go to the office! Our ability to adapt and virtually communicate is due largely to the significant enabler that is technology. For those with a chronic…Read More
RareiTi offers a new managed access model to the pharmaceutical industry, delivering solutions for named patient, compassionate use and expanded access programs to meet the unmet needs of people and communities across the globe impacted by rare disease. Our managed access programs provide care beyond therapy, combining customizable solutions with white glove service and the ability to deliver real world evidence and data from the point of care. We combine a breadth of global experience, cutting edge technologies and analytics to deliver better outcomes.
Our advisory practice offers business advice and recommendations on the suitability, design and business impact of managed access including compassionate use, expanded access and named patient programs for patients with rare diseases.
We deliver customized global managed access designed to meet complex challenges for patients with a rare disease at the point of care.
Latest from RareiTi VIEW
Latest Tweets @RareiTi
An experienced senior leadership team
40+ rare disease conditions
50+ biotech and pharma companies
200+ managed access programs: expanded access, compassionate use and named patient programs
100,000s of patients supported with access to treatment
The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.
Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.